These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

943 related articles for article (PubMed ID: 27765068)

  • 1. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
    Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
    Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer.
    Tomar T; Alkema NG; Schreuder L; Meersma GJ; de Meyer T; van Criekinge W; Klip HG; Fiegl H; van Nieuwenhuysen E; Vergote I; Widschwendter M; Schuuring E; van der Zee AGJ; de Jong S; Wisman GBA
    BMC Med; 2017 Jun; 15(1):116. PubMed ID: 28641578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis.
    Borges S; Döppler H; Perez EA; Andorfer CA; Sun Z; Anastasiadis PZ; Thompson E; Geiger XJ; Storz P
    Breast Cancer Res; 2013 Aug; 15(2):R66. PubMed ID: 23971832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome-wide DNA methylome analysis identifies methylation signatures associated with survival and drug resistance of ovarian cancers.
    Chan DW; Lam WY; Chen F; Yung MMH; Chan YS; Chan WS; He F; Liu SS; Chan KKL; Li B; Ngan HYS
    Clin Epigenetics; 2021 Jul; 13(1):142. PubMed ID: 34294135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.
    Zeller C; Dai W; Steele NL; Siddiq A; Walley AJ; Wilhelm-Benartzi CS; Rizzo S; van der Zee A; Plumb JA; Brown R
    Oncogene; 2012 Oct; 31(42):4567-76. PubMed ID: 22249249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-wide methylation and expression profiling identifies promoter characteristics affecting demethylation-induced gene up-regulation in melanoma.
    Rubinstein JC; Tran N; Ma S; Halaban R; Krauthammer M
    BMC Med Genomics; 2010 Feb; 3():4. PubMed ID: 20144234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant promoter methylation of SPARC in ovarian cancer.
    Socha MJ; Said N; Dai Y; Kwong J; Ramalingam P; Trieu V; Desai N; Mok SC; Motamed K
    Neoplasia; 2009 Feb; 11(2):126-35. PubMed ID: 19177197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
    Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
    Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo.
    Steele N; Finn P; Brown R; Plumb JA
    Br J Cancer; 2009 Mar; 100(5):758-63. PubMed ID: 19259094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
    Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
    Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic and genetic alterations of p33ING1b in ovarian cancer.
    Shen DH; Chan KY; Khoo US; Ngan HY; Xue WC; Chiu PM; Ip P; Cheung AN
    Carcinogenesis; 2005 Apr; 26(4):855-63. PubMed ID: 15677627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells.
    Heller G; Schmidt WM; Ziegler B; Holzer S; Müllauer L; Bilban M; Zielinski CC; Drach J; Zöchbauer-Müller S
    Cancer Res; 2008 Jan; 68(1):44-54. PubMed ID: 18172295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.
    Plumb JA; Strathdee G; Sludden J; Kaye SB; Brown R
    Cancer Res; 2000 Nov; 60(21):6039-44. PubMed ID: 11085525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance.
    Grasse S; Lienhard M; Frese S; Kerick M; Steinbach A; Grimm C; Hussong M; Rolff J; Becker M; Dreher F; Schirmer U; Boerno S; Ramisch A; Leschber G; Timmermann B; Grohé C; Lüders H; Vingron M; Fichtner I; Klein S; Odenthal M; Büttner R; Lehrach H; Sültmann H; Herwig R; Schweiger MR
    Genome Med; 2018 Jul; 10(1):55. PubMed ID: 30029672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells.
    Cardenas H; Vieth E; Lee J; Segar M; Liu Y; Nephew KP; Matei D
    Epigenetics; 2014 Nov; 9(11):1461-72. PubMed ID: 25470663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of candidate methylation-responsive genes in ovarian cancer.
    Menendez L; Walker D; Matyunina LV; Dickerson EB; Bowen NJ; Polavarapu N; Benigno BB; McDonald JF
    Mol Cancer; 2007 Jan; 6():10. PubMed ID: 17254359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic screening for genes upregulated by demethylation revealed novel targets of epigenetic silencing in breast cancer.
    Fujikane T; Nishikawa N; Toyota M; Suzuki H; Nojima M; Maruyama R; Ashida M; Ohe-Toyota M; Kai M; Nishidate T; Sasaki Y; Ohmura T; Hirata K; Tokino T
    Breast Cancer Res Treat; 2010 Aug; 122(3):699-710. PubMed ID: 19859801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma.
    Natsume A; Wakabayashi T; Tsujimura K; Shimato S; Ito M; Kuzushima K; Kondo Y; Sekido Y; Kawatsura H; Narita Y; Yoshida J
    Int J Cancer; 2008 Jun; 122(11):2542-53. PubMed ID: 18240144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma.
    Shi X; Chen X; Fang B; Ping Y; Qin G; Yue D; Li F; Yang S; Zhang Y
    Biomed Pharmacother; 2019 Apr; 112():108632. PubMed ID: 30797153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
    Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
    Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.